Atlas Trials

A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

Clinical trial NCT06554600 · RECRUITING

Trial details

NCT number
NCT06554600
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Refractory or Relapsed Diffuse Large B Cell Lymphoma
Start date
2024-08-31
Primary completion
2026-08-31
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.